Biocon Ltd said on Tuesday it agreed to buy a 7.7 percent stake in its research services business from a unit of GE Capital for 2.15 billion rupees ($35.48 million).
Biocon said it would buy the stake in unit Syngene, which is involved in pharmaceutical contract research and manufacturing, from GE Equity International Mauritius.
Biocon had previously said it planned to take Syngene public, but has not given a timeline.
Zee News App: Read latest news of India and world, bollywood news, business updates, cricket scores, etc. Download the Zee news app now to keep up with daily breaking news and live news event coverage.
